GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%.

We compare these trends to the stock’s performance during the 2008 recession. Notably, GSK stock has underperformed the broader market in each of the last three years. Returns for the stock were ...

In the latest market close, GSK (GSK) reached $41.90, with a -1.04% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day.

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

GSK plc GSK will report its second-quarter earnings on Jul 31, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $9.5 billion and $1.00 per share, respectively.

For new and old investors, taking full advantage of the stock market and investing with confidence are common ... which is more than double the S&P 500's performance over the same time frame. However, ...

Additionally, GSK has a PEG Ratio of 1.2 and a Price/Cash Flow ratio of 7.3X. Value investors should also note GSK's Price/Sales ratio of 2X. A company's earnings performance is important for ...

GSK is a rare undervalued stock in the frothy pharmaceutical sector. It's demonstrating strong operating performance and expects record sales for Shingrix this year.

Hence, let’s take a more factual approach to GSK’s performance and see the current GSK valuation. GSK Q1 2022 results indicated that the biopharma GSK produced £7.1bn and had an adjusted ...

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.